Tevogen Bio Holdings Inc.
NASDAQ: TVGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ryan H. Saadi
- Employees
- 18
- Headquarters
- Warren, United States
- IPO year
- 2022
- Market cap
- $41.4M
- Website
- https://tevogen.com
Loading TVGN…
Loading profile data…Frequently asked questions about TVGN
What does Tevogen Bio Holdings Inc. (TVGN) do?
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19...
Where does TVGN trade?
Tevogen Bio Holdings Inc. (TVGN) trades on the NASDAQ Global Market.
What sector is TVGN in?
Tevogen Bio Holdings Inc. (TVGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tevogen Bio Holdings Inc.?
Ryan H. Saadi is the chief executive officer of Tevogen Bio Holdings Inc. (TVGN).
Where is Tevogen Bio Holdings Inc. headquartered?
Tevogen Bio Holdings Inc. is headquartered in United States.
Does TVGN pay a dividend?
Tevogen Bio Holdings Inc. (TVGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TVGN go public?
Tevogen Bio Holdings Inc. (TVGN) completed its initial public offering in 2022.